北京万东医疗科技股份有限公司 关于取得医疗器械注册证的公告 证券代码：600055 证券简称：万东医疗 编号：临 2024-031 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 北京万东医疗科技股份有限公司（以下简称"公司"）于近日收 到国家药品监督管理局颁发的《中华人民共和国医疗器械注册证》， 具体情况如下： 一、 医疗器械注册证的具体情况 1、注册证编号：国械注准20243062337 注册人名称：北京万东医疗科技股份有限公司 注册人住所：北京市朝阳区酒仙桥东路9号院3号楼 生产地址：北京市朝阳区酒仙桥东路9号院3号楼 产品名称：磁共振成像系统 型号、规格：i_Space 3.0T Plus、i_Space 3.0T Pro 结构及组成：产品由3.0T超导磁体、谱仪、梯度子系统、射频子 系统、接收线圈、患者床、控制台和生理门控组成。 生效日期：二〇二四年十一月二十一日 有效期至：二〇二九年十一月二十日 2、注册证编号：国械注准20243062340 注册人名称：北京万东医疗科技股份有限公司 注册人住所：北京市朝阳区酒仙 ...

证券代码：600055 证券简称：万东医疗 编号：临 2024-032 北京万东医疗科技股份有限公司 关于公司及子公司使用闲置募集资金 及自有资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法 律责任。 重要内容提示： 产品种类：银行理财 本次现金管理总额：募集资金 1.5 亿元、自有资金 4,000 万元 履行的审议程序：2024 年 3 月 21 日召开的第九届董事会第十四次会 议、第九届监事会第十三次会议及 2024 年 4 月 18 日召开的 2023 年年度股 东大会审议批准《关于使用部分暂时闲置募集资金及自有资金进行现金管 理的议案》。 一、情况概述 （一）现金管理目的 北京万东医疗科技股份有限公司（以下简称"公司"）及子公司为提 高募集资金和自有资金效率，合理利用部分闲置募集资金及自有资金，在 确保不影响募集资金项目建设和使用、募集资金和自有资金安全的情况下， 增加公司的收益，为公司及股东获取更多回报。 （二）现金管理金额 本次现金管理总金额为：公司使用募集资金 1.5 亿元；子公司使用自 有 ...

证券代码：600055 证券简称：万东医疗 公告编号：临 2024-030 北京万东医疗科技股份有限公司 关于召开 2024 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2024 年 11 月 4 日(星期一) 下午 16:00-17:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 10 月 28 日(星期一) 至 11 月 1 日(星期五)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 wdm_ir@wandong.com.cn 进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 北京万东医疗科技股份有限公司（以下简称"公司"）拟于 2024 年 10 月 26 日发布公司 2024 年第三季度报告，为便于广大投资者更全面深入地了解公 司 2024 年 ...

Financial Performance - The company's operating revenue for Q3 2024 was ¥392,997,329.14, representing an increase of 18.57% compared to the same period last year[2]. - The net profit attributable to shareholders for Q3 2024 was ¥30,991,596.41, a decrease of 29.79% year-on-year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥30,020,301.79, down 13.71% from the previous year[2]. - Total operating revenue for the first three quarters of 2024 reached CNY 1,093,084,824.41, an increase of 18.1% compared to CNY 925,789,900.33 in the same period of 2023[14]. - Net profit for the third quarter of 2024 was CNY 116,626,283.67, a decrease of 4.9% from CNY 121,823,300.98 in the same quarter of 2023[15]. - Basic and diluted earnings per share for Q3 2024 were both CNY 0.165, slightly down from CNY 0.171 in Q3 2023[16]. Assets and Liabilities - The total assets at the end of Q3 2024 were ¥5,333,855,627.01, a decrease of 1.16% from the end of the previous year[3]. - The total assets of Beijing Wandong Medical Technology Co., Ltd. as of September 30, 2024, amounted to CNY 5,333,855,627.01, a slight decrease from CNY 5,396,325,530.54 at the end of 2023[10]. - The company's total liabilities decreased to CNY 484,350,240.72 from CNY 575,700,678.51 year-over-year, reflecting a reduction of 15.9%[12]. - The total equity attributable to shareholders at the end of Q3 2024 was ¥4,739,461,274.00, an increase of 0.59% from the end of the previous year[3]. - The total equity attributable to shareholders of the parent company increased to CNY 4,739,461,274.00, up from CNY 4,711,473,658.91, representing a growth of 0.6%[13]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥25,376,678.78, down 45.79% year-on-year[2]. - The company's cash flow from operating activities decreased significantly due to reduced sales collections from subsidiaries[6]. - Cash inflow from operating activities for the first three quarters of 2024 was CNY 1,141,789,099.03, down from CNY 1,183,299,855.74 in the same period of 2023, indicating a decline of approximately 3.5%[16]. - Net cash flow from operating activities for the first three quarters of 2024 was CNY 25,376,678.78, significantly lower than CNY 46,814,270.40 in the previous year[16]. - Cash inflow from investment activities for Q3 2024 totaled CNY 589,096,890.44, compared to CNY 850,587,310.47 in Q3 2023, marking a decrease of about 30.7%[17]. - Net cash flow from investment activities for Q3 2024 was -CNY 466,001,126.70, compared to -CNY 413,747,838.88 in Q3 2023, indicating a worsening of investment cash flow[17]. - Cash outflow from financing activities for Q3 2024 was CNY 93,756,378.08, compared to CNY 87,189,830.68 in Q3 2023, showing an increase in financing costs[17]. Expenses - Total operating costs for the first three quarters of 2024 were CNY 973,078,073.01, up 17.9% from CNY 825,712,758.90 in the previous year[14]. - Research and development expenses for the first three quarters of 2024 amounted to CNY 115,518,473.81, an increase of 5.3% compared to CNY 109,772,089.94 in the same period of 2023[14]. - Employee compensation payments increased to CNY 279,072,049.27 in Q3 2024, compared to CNY 234,336,618.23 in Q3 2023, reflecting a rise of approximately 19%[16]. Shareholder Information - The company has not reported any changes in the participation of major shareholders in margin trading or securities lending activities[9]. - There are no significant changes in the shareholder structure or related party transactions reported for the period[9]. Future Outlook - Future outlook includes continued investment in new technologies and market expansion strategies to enhance growth potential[15].

履行的审议程序：2024 年 3 月 21 日召开的第九届董事会第十四次会 议、第九届监事会第十三次会议及 2024 年 4 月 18 日召开的 2023 年年度股 东大会审议批准《关于使用部分暂时闲置募集资金及自有资金进行现金管 理的议案》。 一、情况概述 证券代码：600055 证券简称：万东医疗 编号：临 2024-029 北京万东医疗科技股份有限公司 关于公司及子公司使用闲置 自有资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法 律责任。 重要内容提示： 产品种类：银行理财 本次现金管理总额：自有资金 1.15 亿元 （一）现金管理目的 北京万东医疗科技股份有限公司（以下简称"公司"）及子公司为提 高募集资金和自有资金效率，合理利用部分闲置募集资金及自有资金，在 确保不影响募集资金项目建设和使用、募集资金和自有资金安全的情况下， 增加公司的收益，为公司及股东获取更多回报。 （二）现金管理金额 本次现金管理总金额为：公司使用自有资金 8,000 万元；子公司使用 自有资金 3,500 万元。 （三） ...

证券代码：600055 证券简称：万东医疗 编号：临 2024-028 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法 律责任。 重要内容提示： 产品种类：银行理财 本次现金管理总额：募集资金 1 亿元、自有资金 7,000 万元 履行的审议程序：2024 年 3 月 21 日召开的第九届董事会第十四次会 议、第九届监事会第十三次会议及 2024 年 4 月 18 日召开的 2023 年年度股 东大会审议批准《关于使用部分暂时闲置募集资金及自有资金进行现金管 理的议案》。 一、情况概述 （一）现金管理目的 北京万东医疗科技股份有限公司（以下简称"公司"）及子公司为提 高募集资金和自有资金效率，合理利用部分闲置募集资金及自有资金，在 确保不影响募集资金项目建设和使用、募集资金和自有资金安全的情况下， 增加公司的收益，为公司及股东获取更多回报。 （二）现金管理金额 北京万东医疗科技股份有限公司 关于公司及子公司使用闲置募集资金 及自有资金进行现金管理的进展公告 二、审议程序及相关意见 本次现金管理总金额为：公司使用募集资金 1 亿元、 ...

证券代码：600055 证券简称：万东医疗 公告编号：临 2024-027 北京万东医疗科技股份有限公司 关于召开 2024 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2024 年 08 月 26 日(星期一) 下午 16:00-17:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 08 月 19 日(星期一)至 08 月 23 日(星期五)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 wdm_ir@wandong.com.cn 进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 北京万东医疗科技股份有限公司（以下简称"公司"）拟于 2024 年 8 月 17 日发布公司 2024 年半年度报告，为便于广大投资者更全面深入地了解公司 2024 年半年 ...

Financial Performance - The company's operating revenue for the first half of 2024 reached ¥700,087,495.27, representing a 17.79% increase compared to ¥594,330,937.42 in the same period last year[12]. - The net profit attributable to shareholders for the first half of 2024 was ¥84,741,768.09, an increase of 11.44% from ¥76,040,693.09 in the previous year[12]. - The net profit after deducting non-recurring gains and losses was ¥81,116,658.52, which is a 15.57% increase from ¥70,188,705.60 in the same period last year[12]. - The basic earnings per share for the first half of 2024 was ¥0.121, up 12.04% from ¥0.108 in the same period last year[13]. - The diluted earnings per share also stood at ¥0.121, reflecting a 12.04% increase compared to the previous year[13]. - The weighted average return on net assets increased to 1.79%, up by 0.15 percentage points from 1.64% in the same period last year[13]. - The company achieved operating revenue of 700 million yuan, a year-on-year increase of 17.79%, and a net profit attributable to shareholders of 85 million yuan, up 11.44% year-on-year[25]. - Operating costs increased by 20.17% to ¥423,297,853.96 from ¥352,262,500.81, primarily due to product structure adjustments[28]. - Research and development expenses rose by 22.33% to ¥78,990,672.31, reflecting the company's commitment to increasing R&D investment[28]. - The company reported a profit margin of approximately 12.2% for the first half of 2024, compared to 13.0% in the same period of 2023[66]. Cash Flow and Assets - The net cash flow from operating activities was ¥1,104,792.70, a significant decrease of 95.24% compared to ¥23,207,023.89 in the previous year[12]. - Cash and cash equivalents decreased by 12.21% to ¥3,017,472,241.85, down from ¥3,437,252,568.45 in the previous year[30]. - The company's inventory decreased by 18.26% to ¥308,798,369.73, compared to ¥377,797,133.53 last year[30]. - The total assets at the end of the reporting period were ¥5,294,937,805.61, down 1.88% from ¥5,396,325,530.54 at the end of the previous year[12]. - The total current assets amounted to approximately ¥4.35 billion, a decrease of 1.2% from ¥4.40 billion on December 31, 2023[60]. - The company's cash and cash equivalents decreased to approximately ¥3.02 billion from ¥3.44 billion, representing a decline of 12.2%[60]. - Total liabilities decreased from 575,700,678.51 to 476,560,661.25, a reduction of approximately 17.2%[62]. - The total assets of the company as of June 30, 2024, were approximately ¥5.29 billion, down 1.9% from ¥5.40 billion[61]. Market and Industry Insights - The Chinese medical imaging market reached RMB 95.4 billion in 2021, representing 11.3% of the overall medical device market, making it the third-largest segment[15]. - The CT equipment market in China is projected to grow at a compound annual growth rate (CAGR) of 8.5%, with total sales expected to exceed RMB 30 billion by 2029[17]. - The fixed DR market is expected to grow at a CAGR of 7.2% from 2022 to 2027, while mobile DR is limited to a CAGR of 3.5% due to previous demand surges[18]. - By 2027, the investment scale in the medical equipment sector is expected to increase by over 25% compared to 2023, indicating significant growth potential[16]. - The aging population in China is projected to exceed 400 million by 2035, creating increased demand for medical imaging diagnostics[15]. Strategic Initiatives - The company does not plan to distribute profits or increase capital reserves through stock conversion for the mid-year 2024[2]. - The company is implementing a comprehensive supply chain management upgrade, focusing on strategic procurement and inventory optimization[21]. - The company is developing a lean manufacturing system, utilizing data-driven production management to minimize waste and enhance quality control[21]. - The company aims to enhance healthcare access in rural areas by providing advanced medical equipment and services, supporting the national goal of improving healthcare resource distribution[24]. - The company plans to accelerate its international market expansion by increasing the number of sales and market personnel to cover more blank areas and improve the quality of overseas distributors[26]. Research and Development - The company focuses on enhancing smart imaging AI capabilities to drive hospital transformation and upgrade services[15]. - The company plans to integrate AI into its new liquid hydrogen-free MRI system in 2024, enhancing features like automatic positioning and noise reduction[20]. - The company is advancing its AI medical imaging capabilities, launching automated positioning technologies and AI-based quality control features for imaging reports[24]. - The total investment in R&D projects amounts to CNY 204,628.62 million, with a completion rate of 74.77% for MRI product development[50]. - CT product development has a total investment of CNY 26,693.80 million, achieving a completion rate of 99.69%[50]. Shareholder and Equity Information - The total number of common shareholders as of the end of the reporting period is 29,903[55]. - Midea Group holds 45.46% of the shares, totaling 319,579,981 shares[55]. - The total equity attributable to shareholders decreased from 4,711,473,658.91 to 4,708,469,677.59, a slight decline of approximately 0.06%[62]. - The total equity at the end of the first half of 2024 is CNY 4,710,538,777, showing an increase from CNY 4,617,567,090.85 at the end of the previous year[82]. Compliance and Governance - The company has not reported any major violations or penalties involving its directors, supervisors, senior management, or controlling shareholders during the reporting period[45]. - There were no significant lawsuits or arbitration matters during the reporting period[44]. - The company has committed to ensuring the independence of WanDong Medical in terms of assets, personnel, finance, business, and organization after becoming its controlling shareholder[40]. - The company has pledged to minimize related party transactions with WanDong Medical and ensure fair pricing in unavoidable transactions[44]. Accounting Policies and Financial Reporting - The financial statements are prepared based on the going concern assumption, indicating no significant issues affecting the company's ability to continue operations for at least 12 months[89]. - The company adheres to the accounting standards set by the Ministry of Finance, ensuring that the financial reports accurately reflect its financial position and operating results[91]. - The company has implemented specific accounting policies and estimates tailored to its operational characteristics, particularly in revenue recognition[90]. - The company recognizes revenue from medical device sales upon customer acceptance after installation and inspection, or upon receipt of goods for non-installation products[153].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用的 监管要求》和《上海证券交易所上市公司自律监管指引第 1 号——规范运 作》等有关规定，现将北京万东医疗科技股份有限公司（以下简称"公司"） 2024 年半年度募集资金存放与实际使用情况专项说明如下： 一、募集资金基本情况 证券代码：600055 证券简称：万东医疗 编号：临 2024-026 北京万东医疗科技股份有限公司关于公司 2024 年半年度募集资金存放与实际使用 情况的专项报告 （一）募集资金金额及资金到账情况 经中国证券监督管理委员会《关于核准北京万东医疗科技股份有限公 司非公开发行股票的批复》（证监许可[2022]324号）核准，公司向特定对 象非公开发行人民币普通股（A股）162,244,859股，发行价格为每股12.71 元，募集资金总额2,062,132,157.89元，扣除本次非公开发行承销保荐费、 律师费、会计师费及其他发行费用合计15,845,933.54元（不含增值税进项 税），实际募集 ...

证券代码：600055 证券简称：万东医疗 编号：临 2024-024 北京万东医疗科技股份有限公司 第十届董事会第三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 北京万东医疗科技股份有限公司第十届董事会第三次会议以通讯表决 方式于 2024 年 8 月 16 日召开。本次会议的会议通知及相关资料于 2024 年 8 月 11 日以电子邮件的方式向全体董事发出。会议应到董事 7 人，实到 7 人，公司监事及高管人员出席、列席会议。本次会议的召开符合《公司法》 和《公司章程》的规定，所作决议合法有效。 会议由胡自强董事长主持，形成如下决议： 一、 审议通过《公司 2024 年半年度报告及摘要》。 该议案已经审计委员会事前认可，经审计委员会全体成员一致同意后， 提交董事会审议，具体内容详见上海证券交易所网站。 本议案表决结果：同意 7 票，反对 0 票，弃权 0 票。 二、 审议通过《关于公司 2024 年半年度募集资金存放与实际使用情 况的专项报告》。 具体内容详见公司披露于上海证券交易所网站的（临 2024 ...